文献速递乳腺癌

Patritumab deruxtecan用于未经治疗激素受体阳性/HER2阴性早期乳腺癌:机会窗SOLTI TOT-HER3术前研究A部分最终结果

Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study.
PubMed 文献 · Ann Oncol · 2023-05-19

TOT-HER3是一项机会窗研究,评估单次HER3-DXd 6.4 mg/kg术前治疗激素受体阳性/HER2阴性早期乳腺癌的生物学活性(CelTIL评分变化)和临床活性。77例可评估疗效,CelTIL评分中位较基线升高3.5(四分位距-3.8至12.7,P=0.003);62例可评估临床反应者总缓解率45%(卡尺测量肿瘤)。治疗中出现不良事件96%(14%≥3级)。

要点

  • 单次HER3-DXd 6.4 mg/kg术前治疗使CelTIL评分中位较基线升高3.5(P=0.003)。
  • 可评估临床反应者(n=62)总缓解率45%(卡尺测量肿瘤)。
  • 治疗中出现不良事件96%,≥3级14%;常见恶心、乏力、脱发、腹泻、呕吐、腹痛、中性粒细胞减少。

核心结论

  • 单次HER3-DXd与临床缓解、免疫浸润增加、增殖抑制相关,且安全性可耐受,与既往报告一致;这些发现支持在早期乳腺癌中进一步研究HER3-DXd。

研究设计与样本

  • TOT-HER3是一项机会窗研究,评估短期(21天)术前治疗原发性可手术HER2阴性早期乳腺癌的生物学活性和临床活性。
  • 既往未治疗激素受体阳性/HER2阴性肿瘤患者按基线ERBB3信使RNA表达分配至四个队列之一。
  • 所有患者接受一剂HER3-DXd 6.4 mg/kg。
  • 主要目标为评估CelTIL评分较基线的变化;77例可评估疗效。

主要发现

  • CelTIL评分中位较基线升高3.5(四分位距-3.8至12.7,P=0.003)。
  • 可评估临床反应者(n=62)总缓解率45%(卡尺测量肿瘤),缓解者较非缓解者CelTIL评分有升高趋势(平均差+11.9 vs +1.9)。
  • CelTIL评分变化与基线ERBB3信使RNA和HER3蛋白水平无关。
  • 发生基因组改变,包括基于PAM50亚型向低增殖肿瘤表型转换、细胞增殖基因抑制及免疫相关基因诱导。
  • 治疗中出现不良事件96%(14%≥3级);最常见为恶心、乏力、脱发、腹泻、呕吐、腹痛、中性粒细胞计数减少。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patritumab deruxtecan (HER3-DXd) is a human epidermal growth factor receptor 3 (HER3)-directed antibody-drug conjugate composed of a fully human anti-HER3 monoclonal antibody (patritumab) covalently linked to a topoisomerase I inhibitor payload via a stable, tumor-selective, tetrapeptide-based cleavable linker. TOT-HER3 is a window-of-opportunity study designed to assess the biological activity, measured by CelTIL score [= -0.8 × tumor cellularity (in %) + 1.3 × tumor-infiltrating lymphocytes (TILs) (in %)], and clinical activity of HER3-DXd during short-term (21 days) pre-operative treatment in patients with primary operable HER2-negative early breast cancer. PATIENTS AND METHODS: Patients with previously untreated hormone receptor-positive/HER2-negative tumors were allocated to one of four cohorts according to baseline ERBB3 messenger RNA expression. All patients received one dose of HER3-DXd 6.4 mg/kg. The primary objective was to evaluate change from baseline in CelTIL score. RESULTS: Seventy-seven patients were evaluated for efficacy. A significant change in CelTIL score was observed, with a median increase from baseline of 3.5 (interquartile range, -3.8 to 12.7; P = 0.003). Among patients assessable for clinical response (n = 62), an overall response rate of 45% was observed (tumor measurement by caliper), with a trend toward an increase in CelTIL score among responders compared with non-responders (mean difference, +11.9 versus +1.9). Change in CelTIL score was independent of baseline ERBB3 messenger RNA and HER3 protein levels. Genomic changes occurred, including switching toward a less proliferative tumor phenotype based on PAM50 subtypes, suppression of cell proliferation genes, and induction of genes associated with immunity. Treatment-emergent adverse events were observed in 96% of patients (14% grade ≥3); most common were nausea, fatigue, alopecia, diarrhea, vomiting, abdominal pain, and neutrophil count decrease. CONCLUSIONS: A single dose of HER3-DXd was associated with clinical response, increased immune infiltration, suppression of proliferation in hormone receptor-positive/HER2-negative early breast cancer, and a tolerable safety profile consistent with previously reported results. These findings support further study of HER3-DXd in early breast cancer.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Oliveira M, Falato C, Cejalvo JM, et al. Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study. Ann Oncol. 2023. PMID: 37211044. doi:10.1016/j.annonc.2023.05.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。